Global X S&P Biotech ETF
CURE
Global X S&P Biotech ETF CURE Strategy
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
Global X S&P Biotech ETF News & Analysis
etfs
Thematic ETFs: short-lived trend or long-term investment?
Battery technology. Cybersecurity. Cloud Computing. Exchange-traded funds that focus on a niche sector are in vogue and worth considering but brace for a high-risk/high-reward ride.
etfs
Spotlight on 4 thematic ETFs
These four exchange-traded funds tap into key themes on the international investing landscape: biotech, China's new economy, AI and lithium.
etfs
Thematic ETFs are hot, until they're not
These days there seems to be an exchange-traded fund for every emerging trend and while they are convenient, they are no guarantee of value and growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,633.10 | 66.10 | 0.77% |
| CAC 40 | 7,213.32 | 14.87 | 0.21% |
| DAX 40 | 19,146.17 | 141.39 | 0.74% |
| Dow JONES (US) | 43,870.35 | 461.88 | 1.06% |
| FTSE 100 | 8,149.27 | 64.20 | 0.79% |
| HKSE | 19,295.71 | 305.40 | -1.56% |
| NASDAQ | 18,972.42 | 6.28 | 0.03% |
| Nikkei 225 | 38,360.29 | 334.12 | 0.88% |
| NZX 50 Index | 13,041.90 | 276.66 | 2.17% |
| S&P 500 | 5,948.71 | 31.60 | 0.53% |
| S&P/ASX 200 | 8,393.80 | 70.80 | 0.85% |
| SSE Composite Index | 3,316.66 | 53.74 | -1.59% |